CVS Caremark Corporation
One CVS Drive
Woonsocket
Rhode Island
02895
United States
Tel: 401-765-1500
Fax: 401-766-2917
Website: http://www.cvscaremark.com/
60 articles about CVS Caremark Corporation
-
The pharmacy benefit management subsidiary of CVS Health is favoring Humira’s biosimilars for its major formularies, with AbbVie’s branded product to be nixed on April 1, 2024.
-
A second trial shows Novo Nordisk’s Wegovy improves heart health. Meanwhile, many other drugs are beginning to face generic competition, including from newly approved biosimilars.
-
The consumer healthcare brand is joining the growing biosimilars market in the U.S. with its new subsidiary Cordavis, which will market a Humira biosimilar as its first product.
-
Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
-
CVS Health Corporation Announces Early Results of Maximum Tender Offers and Election of Early Settlement
8/22/2019
The Maximum Tender Offer for the 2020 Maximum Tender Offer Notes is referred to as the "2020 Notes Maximum Tender Offer" and the Maximum Tender Offer for the 2021 Maximum Tender Offer Notes is referred to as "2021 Notes Maximum Tender Offer".
-
Titan Pharmaceuticals Expands Patient Access To Probuphine® Via Specialty Product Distribution Agreement With CVS Caremark
7/9/2019
Titan Pharmaceuticals, Inc. announced that it has executed a specialty product distribution agreement with CVS Caremark, a subsidiary of CVS Health, further expanding access to treatment with Probuphine implant, Titan's novel maintenance treatment for Opioid Use Disorder in eligible patients.
-
Representatives from five of the nation’s biggest pharmacy benefits manager companies faced members of Congress on Tuesday as lawmakers continue to press pharma players on the high costs of prescription drugs in the United States.
-
Representatives from Cigna, CVS, OptumRx, Prime Therapeutics and Humana will meet with Congress regarding prescription drug prices.
-
With the JP Morgan Healthcare Conference ending today, it’s worth noting the word “healthcare” in the title, not “biopharma.” It’s not as if the biotech and pharmaceutical industry isn’t part of healthcare, but BioSpace’s reporting focuses on biopharma. Here’s a look at some of the more healthcar...
-
The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.
-
CVS Health Offering Free Wellness Screenings in Boston
10/31/2018
Annual Project Health events at CVS Pharmacy locations help address access, affordability and quality care in underserved communities
-
“President Trump is taking historic action to bring patients more transparency through consumer advertising,” Azar said in a speech. “We are proposing to require American drug companies for the first time ever to include in their TV advertising the list prices of drugs paid for by Medicare or Med...
-
The U.S. Department of Justice has given preliminary approval for CVS’ $69 billion acquisition of Aetna after Aetna divested its Medicare Part D business.
-
CVS Pharmacy Completes Rollout of Time Delay Safes in All California Stores
10/10/2018
New safes for controlled substances will help combat opioid epidemic, reduce robbery incidents
-
Kenneth Frazier, chief executive officer of Merck, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.
-
Pharma Companies React to Employers and Health Plans Excluding New Therapies Based on Cost
9/25/2018
Recently, a few companies and government programs have decided to enact their own plans that they believe will help bring down the cost of new therapies. Pharmaceutical companies have begun asserting their positions on the topic. -
In March, U.S. insurer Cigna Corporation announced it was acquiring pharmacy benefits manager Express Scripts for approximately $52 billion. On Monday, the Department of Justice (DOJ) approved the merger.
-
Copenhagen-based Zealand Pharma is selling future royalty streams and $85 million in potential commercial milestones for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma.
-
Although there is a general complaint about drug prices, which rocketed into the public domain during the 2016 U.S. presidential election, nothing particularly dramatic has been done about it.